



MINUTES

Kept at the Annual General Meeting held in Uppsala on September 30, 2013 with the shareholders of Oasmia Pharmaceutical AB (556332-6676)

Present according to established voting list

§ 1 Opening of the Meeting

The Meeting was opened by the Chairman of the Board Joel Citron who welcomed all present.

§ 2 Election of Chairman of the meeting

Joel Citron was elected chairman of the meeting. The chairman reported that Jonas Björilin had been chosen as minute keeper.

§ 3 Preparation and approval of the voting list

The list in Appendix 1 was approved as voting list for the meeting.

Non-shareholders were approved to be present at the meeting.

§ 4 Approval of the agenda

The agenda included in the notice (Appendix 2) was approved to constitute the agenda of the meeting.

§ 5 Election of one or two verifiers

The meeting selected the Chairman and Anders Blom as minute verifiers.

§ 6 Determination as to whether the Meeting has been properly convened

It was established that a complete notice for the meeting was inserted into the Post and Inrikes tidningar and on the company website in accordance with the Companies Act and the Articles of Association. A message that notice of Annual General Meeting had been issued was also published in Dagens Nyheter.

The meeting was declared to be properly convened.

Justeras:

Anders Blom

Joel Citron

§ 7 Speech by the Chief Executive President

The Chief Executive Officer Julian Aleksov presented the company's business activities in the past year and answered questions.

§ 8 Presentation of the Annual Report and the Consolidated Accounts as well as the Audit Report and the Audit Report for the Group

The Annual Report, including the Corporate Governance Report, the consolidated accounts, the audit report and the consolidated financial statement for the fiscal year 2012/2013.

§ 9 Resolutions on

a) adoption of the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet

The income statement, balance sheet, consolidated accounts and the consolidated financial statement were established as presented.

b) dispositions in respect of the company's profit/loss pursuant to the adopted Balance Sheet

It was resolved, in accordance with the Board's proposal that no dividends be made and that share premium reserve SEK 573 438 611, accumulated profit of SEK -194 851 017, and profit for the year SEK -72 403 512, in total SEK 306 184 028, shall be brought forward.

c) discharge of liability for the members of the board and Chief Executive Officer

The members of the board and the chief executive officer were discharged of liability for the period comprised by the Annual Report. It was noted that concerned parties were exempted from participation in the resolution.

§ 10 Determination of the number of board members

The representative from the nomination committee Bo Cederstrand presented the nomination committee's proposal in brief. All nominated persons were allowed to present themselves.

It was resolved that the number of board members for the period until the end of the next Annual General Meeting shall be seven and that no deputies shall be appointed.

Verifies:

Joel Citron

Anders Blom

It was resolved in accordance with the Board's proposal. Noted that shareholder Stig Öhman representing 30 463 shares made a reservation against the resolution. It was established that the required majority was achieved.

§ 11 Determination of fee to the Board of Directors and the Auditors

It was resolved that a member of the Board not employed by the company shall receive remuneration amounting to SEK 150 000. The Chairman of the Board shall receive payment of SEK 175 000. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly-owned by the Board member. In that case, the invoiced fee will be increased by the amount of social security contributions and VAT.

It was resolved that remuneration to the auditors shall be paid according to bill

§ 12 Election of Board of Directors, Chairman of the Board of Directors and auditors

It was resolved that Joel Citron, Martin Nicklasson, Jan Lundberg, Horst Domdey, Bo Cederstrand and Julian Aleksov was reelected and Alexander Kotsinas was elected as regular members of the board for the period until the end of the next Annual General Meeting and to reelect Joel Citron as Chairman of the Board. Ernst & Young AB were elected as auditors, with Björn Ohlsson as principal auditor.

§ 13 Decision on the nomination committee prior to the 2013 Annual General Meeting

It was resolved that the following criteria for appointment of the nomination committee for the Annual General Meeting 2014. One member shall represent the largest shareholders. One member shall be independent from the largest shareholders and independent from the company management and the Board of Directors. One member shall be the Chairman of the Board of Directors (convener). The nomination committee's mandate period shall last until a new nomination committee has been appointed. If a member leaves the nomination committee before the assignment has been completed, other members shall appoint a replacement.

§ 14 The Board's proposal for resolution on remuneration guidelines for the Chief Executive Officer and other persons in the company management

It was resolved that guidelines for salary and other remuneration for the Chief Executive Officer and other persons in the company management in accordance with the Board's proposal (Appendix 3).

Verifies:

Joel Citron

Anders Blom

§ 15 The Board’s proposal for decision to issue of warrants to the Board of Directors and the Management

The Board’s proposal of decision of issue of warrants for the Board of Directors and the Management (Appendix 4) was presented.

It was resolved to adopt the proposal from the Board. It was noted that the shareholders Lars Bramelid, Eva Grantinger, Jörgen Allen and the representative from the Shareholders association Josefine Gunnarsdottir representing 9 388 shares in total made reservations against the resolution. It was established that required majority was achieved.

§ 16 The Board’s proposal for the authorization of repurchase and transfer the company’s own shares

The Board’s proposal for the authorization of repurchase and transfer of the company’s own shares (Appendix 5) were presented.

A resolution was made in accordance with the Board’s proposal. It was noted that the shareholders Lars Bramelid and the representative of the Shareholders’ association Josefine Gunnarsdottir representing 62 shares in total made reservations against the resolution. It was established that the required majority was achieved.

§ 17 The Board’s proposal for the authorization of a share issue

The Board’s proposal for the authorization of a share issue (Appendix 6) was presented.

A resolution was made in accordance with the Board’s proposal.

§ 18 Closing of the Meeting

The chairman thanked everyone present and declared the meeting to be closed.

Joel Citron, chairman

Jonas Björlin, secretary

Anders Blom, verifier

Verifies:

Joel Citron

Anders Blom